TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community-Based Cognitive Therapy for Suicide Attempters
Brief Summary: This study will determine the effectiveness of cognitive behavioral therapy (CBT) in preventing future suicide attempts in repeat suicide attempters.


Options:
A: Arm Label: Informational Sessions; Type: SHAM_COMPARATOR; Interventions: Behavioral: Informational sessions describing BPD characteristics | Arm Label: Condensed-DBT treatment intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Condensed-DBT treatment intervention | Intervention Type: BEHAVIORAL; Name: Informational sessions describing BPD characteristics; Assigned to Arm(s): Informational Sessions | Intervention Type: BEHAVIORAL; Name: Condensed-DBT treatment intervention; Assigned to Arm(s): Condensed-DBT treatment intervention
B: Arm Label: Intensive Group Analytic Psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive Group Analytic Psychotherapy | Arm Label: Intensive GCBT; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive transdiagnostic cognitive-behavioral group therapy | Arm Label: Wait-list control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intensive Group Analytic Psychotherapy; Assigned to Arm(s): Intensive Group Analytic Psychotherapy | Intervention Type: BEHAVIORAL; Name: Intensive transdiagnostic cognitive-behavioral group therapy; Assigned to Arm(s): Intensive GCBT
C: Arm Label: Cognitive behavioral therapy (CBT) + standard care; Type: EXPERIMENTAL; Interventions: Behavioral: CBT, Behavioral: Standard care alone | Arm Label: Standard care alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care alone | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): Cognitive behavioral therapy (CBT) + standard care | Intervention Type: BEHAVIORAL; Name: Standard care alone; Assigned to Arm(s): Cognitive behavioral therapy (CBT) + standard care, Standard care alone
D: Arm Label: Care Management; Type: EXPERIMENTAL; Interventions: Behavioral: Care Management | Arm Label: Skills Training; Type: EXPERIMENTAL; Interventions: Behavioral: Skills Training | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Care Management; Assigned to Arm(s): Care Management | Intervention Type: BEHAVIORAL; Name: Skills Training; Assigned to Arm(s): Skills Training | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community-Based Cognitive Therapy for Suicide Attempters
Brief Summary: This study will determine the effectiveness of cognitive behavioral therapy (CBT) in preventing future suicide attempts in repeat suicide attempters.


Options:
A: Arm Label: ALGOS group; Type: EXPERIMENTAL; Interventions: Behavioral: ALGOS algorithm of case management | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ALGOS algorithm of case management; Assigned to Arm(s): ALGOS group
B: Arm Label: Caring Letter Condition (CL); Type: EXPERIMENTAL; Interventions: Behavioral: Caring Letter (email) | Arm Label: Usual Care (UC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Caring Letter (email); Assigned to Arm(s): Caring Letter Condition (CL)
C: Arm Label: Zolpidem-CR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zolpidem-CR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zolpidem-CR; Assigned to Arm(s): Zolpidem-CR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Cognitive behavioral therapy (CBT) + standard care; Type: EXPERIMENTAL; Interventions: Behavioral: CBT, Behavioral: Standard care alone | Arm Label: Standard care alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care alone | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): Cognitive behavioral therapy (CBT) + standard care | Intervention Type: BEHAVIORAL; Name: Standard care alone; Assigned to Arm(s): Cognitive behavioral therapy (CBT) + standard care, Standard care alone

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community-Based Cognitive Therapy for Suicide Attempters
Brief Summary: This study will determine the effectiveness of cognitive behavioral therapy (CBT) in preventing future suicide attempts in repeat suicide attempters.


Options:
A: Arm Label: Internet-based ERITA-DK; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA-DK) | Arm Label: Treatment as Usual (TAU); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA-DK) | Intervention Type: BEHAVIORAL; Name: Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA-DK); Assigned to Arm(s): Internet-based ERITA-DK, Treatment as Usual (TAU)
B: Arm Label: Zolpidem-CR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zolpidem-CR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zolpidem-CR; Assigned to Arm(s): Zolpidem-CR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Iconic Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Emotional regulation | Arm Label: Support therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Emotional regulation | Intervention Type: BEHAVIORAL; Name: Emotional regulation; Assigned to Arm(s): Iconic Therapy, Support therapy
D: Arm Label: Cognitive behavioral therapy (CBT) + standard care; Type: EXPERIMENTAL; Interventions: Behavioral: CBT, Behavioral: Standard care alone | Arm Label: Standard care alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care alone | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): Cognitive behavioral therapy (CBT) + standard care | Intervention Type: BEHAVIORAL; Name: Standard care alone; Assigned to Arm(s): Cognitive behavioral therapy (CBT) + standard care, Standard care alone

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Multicenter, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Tarceva (Erlotinib Hydrochloride) in Combination With Avastin (Bevacizumab) Versus Avastin Alone for Treatment of Metastatic Renal Cell Carcinoma
Brief Summary: The primary purpose of the study is to assess the potential benefit of combining two targeted therapies (an anti-EGF inhibitor along with an anti-VEGF inhibitor). The goal will be to determine whether the addition of Erlotinib to Avastin will improve the benefit in metastatic renal cell carcinoma (RCC) with regard to time to progression, response rate, duration of response, and survival compared with Avastin alone. Since Avastin has been shown to be active in renal cancer, the goal will be to assess whether this activity can be enhanced with Erlotinib.


Options:
A: Arm Label: Savolitinib; Type: EXPERIMENTAL; Interventions: Drug: Savolitinib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Savolitinib; Assigned to Arm(s): Savolitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
B: Intervention Type: DRUG; Name: Avastin (bevacizumab); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Tarceva (erlotinib HCl); Assigned to Arm(s): N/A
C: Arm Label: Arm S: Nivolumab + Sunitinib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Sunitinib | Arm Label: Arm P: Nivolumab + Pazopanib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Pazopanib | Arm Label: Arm I-1: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm I-3: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm IN-3: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm I-1: Nivolumab + Ipilimumab, Arm I-3: Nivolumab + Ipilimumab, Arm IN-3: Nivolumab+Ipilimumab, Arm P: Nivolumab + Pazopanib, Arm S: Nivolumab + Sunitinib | Intervention Type: BIOLOGICAL; Name: Pazopanib; Assigned to Arm(s): Arm P: Nivolumab + Pazopanib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Arm S: Nivolumab + Sunitinib | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm I-1: Nivolumab + Ipilimumab, Arm I-3: Nivolumab + Ipilimumab, Arm IN-3: Nivolumab+Ipilimumab
D: Arm Label: Lenvatinib + Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Pembrolizumab | Intervention Type: DRUG; Name: Lenvatinib; Assigned to Arm(s): Lenvatinib + Pembrolizumab | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Lenvatinib + Pembrolizumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)
Brief Summary: This study will compare medical therapy plus stenting of hemodynamically significant renal artery stenoses versus medical therapy alone in patients with systolic hypertension and renal artery stenosis.


Options:
A: Arm Label: revascularization; Type: ACTIVE_COMPARATOR; Interventions: Procedure: revascularization | Arm Label: medical therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Optimal medical therapy | Intervention Type: DRUG; Name: Optimal medical therapy; Assigned to Arm(s): medical therapy | Intervention Type: PROCEDURE; Name: revascularization; Assigned to Arm(s): revascularization
B: Arm Label: Optimal Medical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atacand/HCT, Caduet | Arm Label: Stenting; Type: EXPERIMENTAL; Interventions: Procedure: GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting) | Intervention Type: DRUG; Name: Atacand/HCT, Caduet; Assigned to Arm(s): Optimal Medical Therapy | Intervention Type: PROCEDURE; Name: GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting); Assigned to Arm(s): Stenting
C: Intervention Type: DEVICE; Name: Renal artery stent; Assigned to Arm(s): N/A
D: Arm Label: STN; Type: EXPERIMENTAL; Interventions: Device: Dynamic Renal Stent plus Best Medical Treatment | Arm Label: BMT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Best Medical Treatment | Intervention Type: DEVICE; Name: Dynamic Renal Stent plus Best Medical Treatment; Assigned to Arm(s): STN | Intervention Type: DRUG; Name: Best Medical Treatment; Assigned to Arm(s): BMT

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Injection of Autologous CD34-Positive Cells for Neovascularization and Symptom Relief in Patients With Myocardial Ischemia
Brief Summary: The purpose of this study is to determine if cell therapy with your own cells (autologous cells) delivered with a catheter to regions of the heart with poor blood flow will be safe and if it will relieve your chest pain and/or your ability to exercise.


Options:
A: Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Biological: Sham, no injection | Arm Label: C3BS-CQR-1 Treated; Type: EXPERIMENTAL; Interventions: Biological: Injection of C3BS-CQR-1 | Intervention Type: BIOLOGICAL; Name: Injection of C3BS-CQR-1; Assigned to Arm(s): C3BS-CQR-1 Treated | Intervention Type: BIOLOGICAL; Name: Sham, no injection; Assigned to Arm(s): Control
B: Arm Label: Myocardial infarction; Type: N/A; Interventions: Other: cell therapy | Arm Label: Ischemic cardiomyopathy; Type: N/A; Interventions: Other: cell therapy | Intervention Type: OTHER; Name: cell therapy; Assigned to Arm(s): Ischemic cardiomyopathy, Myocardial infarction
C: Arm Label: Peripheral; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte-colony stimulating factor | Arm Label: Percutaneous intracoronary injection; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte-colony stimulating factor, Procedure: Percutaneous intracoronary injection | Arm Label: Percutaneous intramyocardial injection; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte-colony stimulating factor, Procedure: Percutaneous intramyocardial injection | Intervention Type: DRUG; Name: Granulocyte-colony stimulating factor; Assigned to Arm(s): Percutaneous intracoronary injection, Percutaneous intramyocardial injection, Peripheral | Intervention Type: PROCEDURE; Name: Percutaneous intracoronary injection; Assigned to Arm(s): Percutaneous intracoronary injection | Intervention Type: PROCEDURE; Name: Percutaneous intramyocardial injection; Assigned to Arm(s): Percutaneous intramyocardial injection
D: Intervention Type: GENETIC; Name: Cell Therapy - Autologous CD34 Positive Cells; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Randomized Trial of a Moxifloxacin-Containing Regimen For Treatment of Smear-Positive Pulmonary Tuberculosis in Adults With and Without HIV Infection
Brief Summary: Current treatment of tuberculosis (TB) requires patients to take four drugs for 8 weeks and then two drugs for 4 months. New drug regimens that are shorter and effective against drug-resistant TB are needed. This study will evaluate whether using the drug moxifloxacin (MOX) in place of ethambutol (EMB) during the first 8 weeks of treatment will effectively treat TB.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Moxifloxacin | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): 1, 2
B: Arm Label: TMC207 Stage 1; Type: EXPERIMENTAL; Interventions: Drug: TMC207, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: Placebo Stage 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: TMC207 Stage 2; Type: EXPERIMENTAL; Interventions: Drug: TMC207, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: Placebo Stage 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Intervention Type: DRUG; Name: TMC207; Assigned to Arm(s): TMC207 Stage 1, TMC207 Stage 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Stage 1, Placebo Stage 2 | Intervention Type: DRUG; Name: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis); Assigned to Arm(s): Placebo Stage 1, Placebo Stage 2, TMC207 Stage 1, TMC207 Stage 2
C: Arm Label: HRZE; Type: ACTIVE_COMPARATOR; Interventions: Drug: isoniazid | Arm Label: MRZE; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol) | Intervention Type: DRUG; Name: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol); Assigned to Arm(s): MRZE | Intervention Type: DRUG; Name: isoniazid; Assigned to Arm(s): HRZE
D: Arm Label: Standard dose rifampisin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Moxifloxacin | Arm Label: High dose rifampisin; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): High dose rifampisin, Standard dose rifampisin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IV Randomized, Multicenter, Open-Label Study to Compare the Safety, Tolerability and Efficacy of Trizivir (Abacavir 300mg, Lamivudine 150mg, and Zidovudine 300mg) BID vs Combivir (Lamivudine 150mg and Zidovudine 300mg) BID Plus Atazanavir 400mg QD in Antiretroviral Naive HIV-1 Infected Subjects Over 48 Weeks
Brief Summary: The aim of this study was to assess whether TRIZIVIR, administered twice-daily was as safe, tolerable and efficacious as a combination of the drugs COMBIVIR administered twice-daily and atazanavir administered once daily. Over the course of 48 weeks, various parameters that measure safety, tolerability and efficacy of the investigational drugs were measured and compared.


Options:
A: Arm Label: Trizivir (TZV) Arm; Type: EXPERIMENTAL; Interventions: Drug: Trizivir | Arm Label: Kaletra Arm; Type: EXPERIMENTAL; Interventions: Drug: Lamivudine/Zidovudine, Drug: Lopinavir/Ritonavir | Arm Label: Nevirapine (NVP) Arm; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Intervention Type: DRUG; Name: Trizivir; Assigned to Arm(s): Trizivir (TZV) Arm | Intervention Type: DRUG; Name: Lamivudine/Zidovudine; Assigned to Arm(s): Kaletra Arm | Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): Kaletra Arm | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): Nevirapine (NVP) Arm
B: Intervention Type: DRUG; Name: Trizivir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atazanavir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combivir; Assigned to Arm(s): N/A
C: Arm Label: maternal nevirapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: maternal placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: No intervention | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): maternal nevirapine | Intervention Type: DRUG; Name: No intervention; Assigned to Arm(s): maternal placebo
D: Intervention Type: DRUG; Name: Abacavir; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Open-Label Study to Assess the Durability and Safety of the Prevention of Bone Loss by Treatment With GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids
Brief Summary: Open label safety and efficacy follow-up.


Options:
A: Intervention Type: DRUG; Name: Prasterone (GL701); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Prasterone (GL701); Assigned to Arm(s): N/A
C: Arm Label: real drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dehydroepiandrosterone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Dehydroepiandrosterone; Assigned to Arm(s): real drug | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo patch | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Testosterone (transdermal patches) | Intervention Type: DRUG; Name: Testosterone (transdermal patches); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo patch; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Brief Summary: RATIONALE: The MAP.3 study was designed to test whether hormone therapy using exemestane may prevent breast cancer by blocking the production of estrogen.

PURPOSE: The study protocol was amended in May 2011 and the current purpose of the study is to allow all study participants the opportunity to complete 5 years of exemestane.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aspirin, Drug: Vitamin E | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Behavioral: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Aspirin, Behavioral: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Vitamin E; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Placebo; Assigned to Arm(s): 2, 3, 4
B: Arm Label: Exemestane; Type: OTHER; Interventions: Drug: exemestane | Intervention Type: DRUG; Name: exemestane; Assigned to Arm(s): Exemestane
C: Intervention Type: DRUG; Name: raloxifene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Arm Label: Arm I (2.5 mg letrozole); Type: EXPERIMENTAL; Interventions: Drug: letrozole, Other: quality-of-life assessment, Other: laboratory biomarker analysis | Arm Label: Arm II (1.0 mg letrozole); Type: EXPERIMENTAL; Interventions: Drug: letrozole, Other: quality-of-life assessment, Other: laboratory biomarker analysis | Arm Label: Arm III (0.25 mg letrozole); Type: EXPERIMENTAL; Interventions: Drug: letrozole, Other: quality-of-life assessment, Other: laboratory biomarker analysis | Arm Label: Arm IV (2.5 mg letrozole); Type: EXPERIMENTAL; Interventions: Drug: letrozole, Other: quality-of-life assessment, Other: laboratory biomarker analysis | Intervention Type: DRUG; Name: letrozole; Assigned to Arm(s): Arm I (2.5 mg letrozole), Arm II (1.0 mg letrozole), Arm III (0.25 mg letrozole), Arm IV (2.5 mg letrozole) | Intervention Type: OTHER; Name: quality-of-life assessment; Assigned to Arm(s): Arm I (2.5 mg letrozole), Arm II (1.0 mg letrozole), Arm III (0.25 mg letrozole), Arm IV (2.5 mg letrozole) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Arm I (2.5 mg letrozole), Arm II (1.0 mg letrozole), Arm III (0.25 mg letrozole), Arm IV (2.5 mg letrozole)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: UARK 98-036, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Smoldering/Indolent Myeloma
Brief Summary: The purpose of this research is to study how helpful the combination of thalidomide and Pamidronate or thalidomide and Zometa is in controlling the myeloma disease and to study any side effects.


Options:
A: Arm Label: Arm I: Thal/ZLD; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide, Drug: zoledronic acid | Arm Label: Arm II: ZLD; Type: EXPERIMENTAL; Interventions: Drug: zoledronic acid | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): Arm I: Thal/ZLD | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): Arm I: Thal/ZLD, Arm II: ZLD
B: Arm Label: Thalidomide + Bisphosphonate; Type: EXPERIMENTAL; Interventions: Drug: Pamidronate, Drug: Thalidomide, Drug: Zometa | Intervention Type: DRUG; Name: Pamidronate; Assigned to Arm(s): Thalidomide + Bisphosphonate | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): Thalidomide + Bisphosphonate | Intervention Type: DRUG; Name: Zometa; Assigned to Arm(s): Thalidomide + Bisphosphonate
C: Arm Label: zoledronic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: zoledronic acid | Arm Label: denosumab; Type: EXPERIMENTAL; Interventions: Biological: denosumab | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): zoledronic acid | Intervention Type: BIOLOGICAL; Name: denosumab; Assigned to Arm(s): denosumab
D: Intervention Type: DRUG; Name: pamidronate; Assigned to Arm(s): N/A

Answer: B